This post was originally published on this site Using diagnostic images, artificial intelligence is better able to predict ovarian cancer survival than other current prognostic methods, a study suggests. The study, “A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer,” was published in Nature Communications. A diagnosis of ovarian cancer…
This post was originally published on this site Olympic gymnast and ovarian cancer survivor Shannon Miller will be the keynote speaker March 15 for the second annual Ovarian Cancer Heroes event. Three individuals will be honored at the event, being held at the Hawaii Convention Center in Honolulu during the Society of Gynecologic Oncology (SGO) Annual…
This post was originally published on this site Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a study of two clinical trials suggests. The study, “Once-Weekly Versus Twice-Weekly Carfilzomib In Patients With Newly Diagnosed Multiple Myeloma: A Pooled Analysis Of…
This post was originally published on this site Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells against blood and solid cancers. Under the terms of the agreement, the companies will test Editas’ CRISPR technology as a means to engineer Gamida’s…
This post was originally published on this site In 2003, Don Wright received a daunting diagnosis of multiple myeloma. But not only has the 78-year-old survived, he has thrived. He’s since run 100 marathons, and is preparing for June’s National Senior Games. The founder of eRace Cancer, a social media campaign to educate patients about advances…
This post was originally published on this site Multiple myeloma patients who receive Ninlaro (ixazomib) maintenance after responding to their initial treatment live longer without their disease worsening or returning than patients given a placebo, a Phase 3 clinical trial shows. The TOURNALINE-MM3 trial (NCT02181413), where Ninlaro reduced the risk of disease progression or death by…
This post was originally published on this site To raise awareness of multiple myeloma and efforts to cure it, the International Myeloma Foundation (IMF) is gearing up for the start of Myeloma Action Month (MAM) on March 1. Hoping to involve patients and their families and the myeloma community at large, this year’s activities will focus…
This post was originally published on this site Low-dose photon irradiation, commonly used in radiotherapy, potentially helps malignant pleural mesothelioma (MPM) cells spread, warns a study by Germany’s University of Heidelberg. The study, “Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells,” appeared in the journal Oncotarget. It was based on research led by…
This post was originally published on this site Researchers have found that patients with malignant pleural mesothelioma (MPM) and asbestosis — a chronic lung disease caused by asbestos inhalation — have low levels of certain microRNAs (miRNAs) in blood and tissue samples, indicating that such miRNAs could be used as biomarkers to diagnose these diseases. miRNAs…
This post was originally published on this site The risk of developing or dying from some cancers increases steadily over time. Scientists thought that was the case with malignant pleural mesothelioma, too, but an Italian study shows the risk plateaus four decades after workers are exposed to asbestos. The risk of peritoneal mesothelioma, on the other…
